MCF Advisors
PLX icon

MCF Advisors’s Protalix BioTherapeutics PLX Stock Holding History

MCF Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-10,000
Closed -$23.3K – 1064
2026
Q2 		$23.3K Buy
+10,000
New +$21.2K ﹤0.01% 865

Other funds holding PLX

Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
OGF
Orin Green Financial San Diego, California $267M AUM 12.91% 1-Year Est. Return
Kestra Advisory Services
Kestra Advisory Services Austin, Texas $35.1B AUM 20.13% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

MCF Advisors's PLX Position: Q3 2026 in Review

MCF Advisors sold out of Protalix BioTherapeutics (PLX) in Q3 2026, closing a stake of 10,000 shares — an estimated $23.3K sold.

MCF Advisors first reported a position in PLX in Q2 2026 and held it in 1 quarter. The position peaked at $23.3K in Q2 2026. 22 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • MCF Advisors reported no remaining Protalix BioTherapeutics position as of Q3 2026 after selling out during the quarter.
  • MCF Advisors sold 10,000 Protalix BioTherapeutics shares in Q3 2026, an estimated $23.3K.
  • MCF Advisors first reported a position in Protalix BioTherapeutics in Q2 2026 and held it in 1 quarter.
  • MCF Advisors's Protalix BioTherapeutics position peaked at $23.3K in Q2 2026.
  • 22 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on MCF Advisors's 13F filing for Q3 2026, filed 28 Oct 2026.